News Releases

Date Title  
Toggle Summary AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain
REDWOOD CITY, Calif. , Nov. 16, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a manuscript
Toggle Summary AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results
- $67.9 million of cash and cash equivalents at September 30, 2017 - Type A FDA meeting requested and Briefing Book submitted to FDA regarding DSUVIA complete response letter (CRL) REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Toggle Summary AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department
REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a manuscript
Toggle Summary AcelRx Pharmaceuticals to Hold Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 9th
REDWOOD CITY, Calif. , Oct. 30, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 9th .
Toggle Summary AcelRx's DSUVIA™ Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY® 2017
DSUVIA clinical trial results was one of the top eight abstracts featured as an oral presentation at an opioid pharmacotherapy symposium at ANESTHESIOLOGY® 2017 REDWOOD CITY, Calif. , Oct. 20, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical,
Toggle Summary AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA
REDWOOD CITY, Calif. , Oct. 12, 2017 /PRNewswire/--  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) regarding its New Drug Application
Toggle Summary AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
REDWOOD CITY, Calif. , Sept. 6, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Vincent
Toggle Summary AcelRx Pharmaceuticals Reports Successful Outcome of ZALVISO Phase 3 IAP312 Study on Device Functionality
- Study Objective Achieved with 2.2% of Patients Experiencing a Device Error - - AcelRx Remains on Track to Resubmit NDA by End of 2017 - REDWOOD CITY, Calif., Aug. 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Aug. 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today provided a business update
Toggle Summary AcelRx Pharmaceuticals to Hold a Conference Call and Webcast on Tuesday, August 1st to Discuss ZALVISO Phase 3 Top-line Data and Quarterly Financial Results
REDWOOD CITY, Calif., July 31, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that it will
Toggle Summary AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
REDWOOD CITY, Calif., July 19, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced the appointment of Raffi
Toggle Summary AcelRx Pharmaceuticals' ZALVISO Recognized for Innovative Design with Prestigious Red Dot Award
REDWOOD CITY, Calif., June 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that ZALVISO
Toggle Summary AcelRx Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference
REDWOOD CITY, Calif., May 31, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Vincent J.
Toggle Summary AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
- NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg) and MAA for ARX-04 under review at respective agencies - REDWOOD CITY, Calif., May 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development
Toggle Summary AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May 8th, 2017
REDWOOD CITY, Calif. , April 26, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that it will
Toggle Summary AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual Patient-Controlled Analgesia Systems
REDWOOD CITY, Calif. , April 13, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that Grunenthal, the
Toggle Summary AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRA's Annual Regional Anesthesiology and Acute Pain Medicine Meeting
REDWOOD CITY, Calif. , April 6, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that efficacy and integrated
Toggle Summary European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain
CHMP Opinion Expected First Half 2018 REDWOOD CITY, Calif. , March 28, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain,
Toggle Summary AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April
REDWOOD CITY, Calif. , March 17, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Senior
Toggle Summary AcelRx Pharmaceuticals Presents Efficacy and Pharmacokinetics of DSUVIA™ at Upcoming Congresses
REDWOOD CITY, Calif. , March 16, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, will present data from the DSUVIA™
Toggle Summary AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results
- DSUVIA NDA Accepted and PDUFA Date Set for October 12, 2017 - REDWOOD CITY, Calif. , March 2, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment
Toggle Summary AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in March
REDWOOD CITY, Calif. , March 1, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Timothy
Toggle Summary AcelRx Pharmaceuticals' New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of October 12, 2017
REDWOOD CITY, Calif. , Feb. 27, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the U.S.
Toggle Summary AcelRx Pharmaceuticals to Hold Annual 2016 Financial Results Conference Call and Webcast on Thursday, March 2nd, 2017
REDWOOD CITY, Calif. , Feb. 23, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it will release fourth
Toggle Summary AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
- Howie Rosen to Continue on Board of Directors - REDWOOD CITY, Calif. , Feb. 16, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe
Toggle Summary AcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA™ for Use in Burn Victims with Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif. , Feb. 13, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming podium presentation
Toggle Summary AcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February
REDWOOD CITY, Calif. , Feb. 7, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Timothy E.
Toggle Summary AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain
· Expected FDA Acceptance of the NDA · Planned Submission of MAA in the EU · Potential Approval and Commercialization in the U.S. REDWOOD CITY, Calif. , Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Announces DSUVIA™ as Brand Name for ARX-04 in the United States
REDWOOD CITY, Calif. , Jan. 8, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that the U.S.
Toggle Summary AcelRx Pharmaceuticals Submits New Drug Application for ARX-04 for the Treatment of Moderate-To-Severe Acute Pain
REDWOOD CITY, Calif. , Dec. 13, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it has submitted a New
Toggle Summary AcelRx Pharmaceuticals Reports on ARX-04 Market and Landscape Presented at Analyst & Investor Event
- Peak revenue opportunity for ARX-04 estimated to be $1.1 billion - NDA for ARX-04 on track for submission by year-end REDWOOD CITY, Calif. , Dec. 6, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc . (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Updates Agenda for Analyst & Investor Event Focusing on Innovative Therapies for Treatment of Acute Pain
New speakers are: - Dr. Nathaniel Katz, CEO of Analgesic Solutions; Regulatory and Clinical Pain Expert - Dr. David Leiman, President of AIPM of Houston and Director of HD Research Corp.; Anesthesiologist and Principle Investigator REDWOOD CITY, Calif. , Nov.
Toggle Summary AcelRx Pharmaceuticals Unveiling Results of ARX-04 SAP303 Study in Post-Operative Setting at the Annual ASRA Pain Medicine Meeting
REDWOOD CITY, Calif. , Nov. 17, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming presentation at
Toggle Summary AcelRx Pharmaceuticals to Host Analyst & Investor Event on December 1, 2016
- Expert panel to discuss market opportunity in emergency medicine for investigational agent ARX-04 (sufentanil sublingual tablet, 30 mcg) for the treatment of moderate-to-severe acute pain REDWOOD CITY, Calif. , Nov. 9, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.
Toggle Summary AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in November
REDWOOD CITY, Calif. , Nov. 8, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that senior
Toggle Summary AcelRx Pharmaceuticals Provides Corporate Update and Reports Third Quarter and Nine Months 2016 Financial Results
REDWOOD CITY, Calif. , Nov. 1, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported
Toggle Summary AcelRx Pharmaceuticals to Present ARX-04 Analysis for Treatment of Moderate-to-Severe Acute Pain in Obese Patients at The Obesity Society Annual Meeting
REDWOOD CITY, Calif. , Oct. 31, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming poster presentation
Toggle Summary AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Tuesday, November 1st, 2016
REDWOOD CITY, Calif. , Oct. 25, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release Third Quarter financial
Toggle Summary AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings at National Conference on Correctional Health Care
REDWOOD CITY, Calif. , Oct. 24, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming poster presentation
Toggle Summary AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine
REDWOOD CITY, Calif. , Sept. 28, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that the Company and
Toggle Summary AcelRx Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain
REDWOOD CITY, Calif. , Sept. 27, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the initiation of the
Toggle Summary Findings from AcelRx Pharmaceuticals' Phase 3 SAP301 Study of ARX-04 in Abdominoplasty Patients to be Presented at Plastic Surgery Meeting
REDWOOD CITY, Calif. , Sept. 22, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Dr.
Toggle Summary AcelRx Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference
REDWOOD CITY, Calif. , Sept. 22, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Howie Rosen , chief
Toggle Summary AcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303
- Majority of Patients Had No Adverse Event; Similar Across All Subgroups - Pain Intensity Was Reduced by 27% at 1 Hour, 49% at 2 Hours, 57% at 12 Hours - Phase 3 Program Now Complete; AcelRx Intends to Submit ARX-04 NDA This Year REDWOOD CITY, Calif. , Sept.
Toggle Summary AcelRx Pharmaceuticals to Announce Topline Results in Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain
Management to host conference call tomorrow at 9:00 a.m. ET (6:00 a.m. PT) Thursday, September 15th REDWOOD CITY, Calif. , Sept. 14, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) a specialty pharmaceutical company focused on the development and commercialization of innovative
Toggle Summary AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
REDWOOD CITY, Calif. , Aug. 31, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Timothy E.
Toggle Summary AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries
REDWOOD CITY, Calif. , Aug. 29, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting results from the Phase 3 SAP302 study of ARX-04 (sufentanil sublingual tablet, 30 mcg) in 76 patients who were treated for
Toggle Summary AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain
- Topline SAP302 Results Presented at Military Health System Research Symposium - REDWOOD CITY, Calif. , Aug. 15, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the
Toggle Summary AcelRx Pharmaceuticals to Present Initial Results of Phase 3 Study of ARX‑04 at World Congress of Mountain & Wilderness Medicine
REDWOOD CITY, Calif. , Aug 1, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting top-line results from the initial cohort of 40 patients in single-arm, open-label Phase 3 SAP302 study, which assessed ARX-04
Toggle Summary AcelRx Pharmaceuticals Provides Corporate Update and Reports Second Quarter and Six Months 2016 Financial Results
REDWOOD CITY, Calif. , July 28, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a corporate update and reported
Toggle Summary AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, July 28th, 2016
REDWOOD CITY, Calif . , July 26, 2016 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release Second Quarter
Toggle Summary AcelRx Pharmaceuticals to Present at Cantor Fitzgerald 2nd Annual Healthcare Conference
REDWOOD CITY, Calif. , July 6, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Executive Officer, Howard
Toggle Summary AcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain
- Top-line results expected in Q3 2016 - REDWOOD CITY, Calif. , June 28, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain,
Toggle Summary AcelRx Pharmaceuticals Joins Russell 3000 and Russell 2000 Indexes
REDWOOD CITY, Calif. , June 27, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that the company has joined the
Toggle Summary AcelRx Pharmaceuticals to Participate in Three Upcoming Healthcare Investor Events in June
REDWOOD CITY, Calif. , June 2, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at
Toggle Summary AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 following Ambulatory Abdominal Surgeries at Euroanaesthesia
REDWOOD CITY, Calif. , May 26, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting Phase 3 SAP301 study results at Euroanaesthesia 2016, which is taking place in London, UK on May 28-30, 2016 .
Toggle Summary New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $140
Results to be Presented at the 21st ISPOR Annual International Meeting REDWOOD CITY, Calif. , May 24, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today reported that the Company will be presenting an evaluation of the cost of delivering IV opioids in the emergency department
Toggle Summary AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX‑04 by Type of Abdominal Surgery
REDWOOD CITY, Calif. , May 6, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting a subgroup analysis of the Phase 3 SAP301 study results by surgery type (abdominoplasty, hernioplasty and laparoscopic abdominal
Toggle Summary AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in May
REDWOOD CITY, Calif. , May 4, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at
Toggle Summary AcelRx Pharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results
REDWOOD CITY, Calif. , May 2, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported
Toggle Summary AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 2nd, 2016
REDWOOD CITY, Calif. , April 28, 2016 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release First Quarter
Toggle Summary AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
Conference call update at 4:30pm ET today REDWOOD CITY, Calif. , March 29, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute
Toggle Summary AcelRx Publishes a Review of Hospital-Based Opioid Patient-Controlled Analgesia, Risks and Pharmacoeconomics
- Zalviso Clinical Program Highlighted in Publication in Hospital Pharmacy - REDWOOD CITY, Calif. , March 25, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the
Toggle Summary AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
REDWOOD CITY, Calif. , March 14, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced the initiation of the
Toggle Summary AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results
REDWOOD CITY, Calif. , March 7, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported
Toggle Summary AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif. , March 7, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today that patient enrollment
Toggle Summary AcelRx Pharmaceuticals to Hold Annual 2015 Financial Results Conference Call and Webcast on Monday, March 7th, 2016.
REDWOOD CITY, Calif. , March 3, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that it will release fourth quarter and
Toggle Summary AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in March
REDWOOD CITY, Calif. , March 1, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Senior Management will be presenting at
Toggle Summary AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis
REDWOOD CITY, Calif. , Feb. 25, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today reported encouraging interim
Toggle Summary AcelRx Pharmaceuticals Presents Phase 3 Results from ARX-04 Clinical Program at JAB Burn and Wound Care Symposium
REDWOOD CITY, Calif. , Feb. 11, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a podium presentation will be made at the 38th annual John A. Boswick , M.D. Burn and Wound Care Symposium, which is being held February 14-18, 2016 in Hawaii .
Toggle Summary AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February
REDWOOD CITY, Calif. , Feb. 3, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer and Head of
Toggle Summary AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery
Phase 3 Clinical Data Highlights Safety and Efficacy of Sublingual Sufentanil in Outpatient Abdominal Surgery Populations REDWOOD CITY, Calif. , Jan. 21, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made at the annual European
Toggle Summary AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones
- ARX-04 ER and Postoperative Study Results, NDA Submission - Initiation and Completion of Final Phase 3 trial in the U.S. for Zalviso, NDA Resubmission - Zalviso™ Commercial Launch in the European Union REDWOOD CITY, Calif. , Jan. 10, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Toggle Summary AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso™ in 1Q 2016
REDWOOD CITY, Calif. , Jan. 8, 2016 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported that the Company has received comments
Toggle Summary AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency
REDWOOD CITY, Calif. , Dec. 23, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products
Toggle Summary AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04
- AcelRx Anticipates the Submission of the ARX-04 New Drug Application in the Second Half of 2016 - FDA Agrees to Include a Significant Number of Patients from the Zalviso Studies into the ARX‑04 Safety Database REDWOOD CITY, Calif. , Dec. 14, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.
Toggle Summary AcelRx Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 23, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that AcelRx Co-founder and Chief Medical
Toggle Summary AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting
REDWOOD CITY, Calif. , Nov. 19, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced today that a moderated poster presentation will
Toggle Summary AcelRx Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference
REDWOOD CITY, Calif. , Nov. 10, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer Tim Morris
Toggle Summary AcelRx Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 5, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer Tim Morris will
Toggle Summary AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients
REDWOOD CITY, Calif. , Nov. 4, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, will be presenting at ObesityWeek 2015 an analysis from
Toggle Summary AcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results
REDWOOD CITY, Calif. , Oct. 29, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial
Toggle Summary AcelRx Pharmaceuticals to Hold Business Update and Third Quarter Financial Results Conference Call and Webcast on Thursday, Oct 29th, 2015
REDWOOD CITY, Calif. , Oct 26, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that it will release Third Quarter financial
Toggle Summary AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 mcg Program At The American Society Of Anesthesiology Meeting
Presentation of Clinical Data from Recently Completed Phase 3 Study in Ambulatory Surgery Patients Highlights Efficacy and Tolerability of ARX-04 30 mcg REDWOOD CITY, Calif. , Oct. 23, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made
Toggle Summary AcelRX Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting
Clinical Data from Phase 2 and Phase 3 Development Programs Highlight Efficacy and Tolerability of Sublingual Sufentanil in Out-patient Surgical Populations REDWOOD CITY, Calif. , Oct. 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be
Toggle Summary AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso
REDWOOD CITY, Calif. , Oct. 8, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a regulatory update on Zalviso™ (sufentanil
Toggle Summary AcelRx Pharmaceuticals Announces Initiation of Clinical Study with ARX-04 in Emergency Room Patients with Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif. , Oct. 6, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the
Toggle Summary AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy
REDWOOD CITY, Calif. , Oct. 1, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced the appointment of Gina Ford , RPh to the
Toggle Summary AcelRx Pharmaceuticals to Host Analyst & Investor Event on October 2, 2015
REDWOOD CITY, Calif. , Sept. 24, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that the company will host an Analyst &
Toggle Summary AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso™ for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients
Approval triggers $15 million milestone payment to AcelRx from Grunenthal REDWOOD CITY, Calif. , Sept. 22, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx) announced today that the European Commission (EC) has approved Zalviso™ (15 micrograms sufentanil sublingual tablets)
Toggle Summary AcelRx Pharmaceuticals Receives $65 Million from the Partial Sale of Zalviso™ European Royalties and Commercial Milestones to PDL BioPharma
REDWOOD CITY, Calif. , Sept. 21, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the monetization of the
Toggle Summary AcelRx Pharmaceuticals' ARX-04 Meets all Endpoints in Pivotal Phase 3 Study for Moderate-to-Severe Acute Pain
Detailed SAP301 Results to be Presented at the American Society of Anesthesiologists Annual Meeting October 24-28, 2015 in San Diego, CA. REDWOOD CITY, Calif. , Sept. 9, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development
Toggle Summary AcelRx Pharmaceuticals to Participate at Three Investor Conferences In September
REDWOOD CITY, Calif. , Aug. 26, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will
Toggle Summary AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results
REDWOOD CITY, Calif. , Aug. 3, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial
Toggle Summary AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015.
REDWOOD CITY, Calif. , July 29, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release
Toggle Summary AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients
REDWOOD CITY, Calif. , July 24, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for Zalviso™ (sufentanil sublingual
Toggle Summary Zalviso™ Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain
Results indicate Zalviso controlled moderate-to-severe acute pain following orthopedic surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif. , July 2, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
Toggle Summary AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June
REDWOOD CITY, Calif. , May 22, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that interim chief executive
Toggle Summary AcelRx Awarded Contract from Department of Defense to Advance ARX-04
REDWOOD CITY, Calif. , May 14, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced it has entered into Contract No.
Toggle Summary AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results
REDWOOD CITY, Calif. , May 4, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided a regulatory update on
Toggle Summary AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May
REDWOOD CITY, Calif. , May 1, 2015   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E.
Toggle Summary AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 4th, 2015
REDWOOD CITY, Calif. , April 30, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release
Toggle Summary AcelRx Pharmaceuticals Announces Presentation Of Sublingual Sufentanil Data At The Society of American Gastrointestinal and Endoscopic Surgeons Meeting
Clinical Data from Two Different Development Programs Highlight Efficacy and Tolerability of Sublingual Sufentanil in Out-patient and In-patient Surgical Populations REDWOOD CITY, Calif. , April 14, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a poster
Toggle Summary AcelRx Appoints Howard B. Rosen as Interim CEO
AcelRx Announces Restructuring to Focus on Regulatory Approval of Zalviso and Clinical Development of ARX-04 REDWOOD CITY, Calif. , March 20, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04
SAP301 Trial to Study Sufentanil Sublingual Single-Dose Tablet for the Treatment of Moderate-to-Severe Acute Pain REDWOOD CITY, Calif. , March 16, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
REDWOOD CITY, Calif. , March 9, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported financial results for the three
Toggle Summary AcelRx Provides Regulatory Update on Zalviso
REDWOOD CITY, Calif. , March 9, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided an update on the timing and
Toggle Summary AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015
REDWOOD CITY, Calif. , March 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth
Toggle Summary AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events
REDWOOD CITY, Calif. , Feb. 20, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E.
Toggle Summary AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference
REDWOOD CITY, Calif. , Feb. 4, 2015 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris,
Toggle Summary AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso
REDWOOD CITY, Calif. , Dec. 2, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark
Toggle Summary AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events
REDWOOD CITY, Calif. , Nov. 20, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management
Toggle Summary AcelRx Pharmaceuticals Announces Zalviso™ Sublingual Sufentanil Data Presentation At The American Society Of Regional Anesthesia And Pain Medicine Meeting
Data from Sublingual Sufentanil Tablet System Development Program Highlights Efficacy across Various Demographic Populations REDWOOD CITY, Calif. , Nov. 13, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results
REDWOOD CITY, Calif. , Nov. 10, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results
Toggle Summary AcelRx Pharmaceuticals Receives International Standards Organization (ISO) 13485:2003 Certification of its Quality Management System
REDWOOD CITY, Calif. , Nov. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has been granted
Toggle Summary AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
REDWOOD CITY, Calif. , Nov. 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will
Toggle Summary AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Monday, November 10, 2014
REDWOOD CITY, Calif. , Nov. 6, 2014 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third
Toggle Summary Acelrx Pharmaceuticals Announces Management Change
REDWOOD CITY, Calif. , Nov. 5, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the departure of Richard
Toggle Summary AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting
Data from Sublingual Sufentanil Development Program Highlights Analgesic Response Compared to IV Morphine in Young vs Elderly Adult Patients REDWOOD CITY, Calif. , Oct. 27, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations
Toggle Summary AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results
Results indicate Zalviso controlled moderate-to-severe acute pain following abdominal surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif. , Oct. 22, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that results from the  IAP310 study
Toggle Summary AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso™ and its Proprietary Platform Technologies
Patent estate includes thirteen issued U.S. patents, thirty patents worldwide REDWOOD CITY, Calif. , Oct. 16, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the
Toggle Summary AcelRx Pharmaceuticals Announces Multiple Sublingual Sufentanil Data Presentations At The American Society Of Anesthesiologists Meeting
Data from Sublingual Sufentanil Development Program Highlights Onset of Analgesia, Safety and Effect of Gender on Analgesic Response REDWOOD CITY, Calif. , Oct. 10, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be
Toggle Summary Sufentanil sublingual tablet system study results to be presented at the International Association for the Study of Pain Meeting
REDWOOD CITY, Calif. , Oct. 6, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that a new data analysis
Toggle Summary AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso™
REDWOOD CITY, Calif. , Sept. 26, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans
Toggle Summary AcelRx Announces Publication of Manuscript Analyzing Cost of Intravenous Patient-Controlled Analgesia with Opioids
REDWOOD CITY, Calif. , Sept. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the publication of a
Toggle Summary AcelRx Announces Publication of Sufentanil Sublingual Tablet System vs. Intravenous Patient-Controlled Analgesia with Morphine for Postoperative Pain Study Results
REDWOOD CITY, Calif. , Sept. 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the publication of the
Toggle Summary AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
REDWOOD CITY, Calif. , Aug. 27, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management
Toggle Summary AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results
REDWOOD CITY, Calif. , Aug. 11, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results
Toggle Summary AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
REDWOOD CITY, Calif. , Aug. 8, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will
Toggle Summary AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Monday, August 11th, 2014.
REDWOOD CITY, Calif. , Aug. 7, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release second
Toggle Summary AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso™
REDWOOD CITY, Calif. , July 25, 2014 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S.
Toggle Summary AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso
REDWOOD CITY, Calif. , July 24, 2014 /PRNewswire/ --   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today confirmed the PDUFA date for
Toggle Summary AcelRx and Grunenthal Announce Submission of European Marketing Authorization Application for ZALVISO™
- MAA submission triggers $5 million milestone payment to AcelRx REDWOOD CITY, Calif. and AACHEN, Germany , July 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the
Toggle Summary AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference
REDWOOD CITY, Calif. , June 19, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management
Toggle Summary Results of Cost Analysis Study Presented at ISPOR Meeting Identify Intravenous Patient-Controlled Analgesia (IV PCA) Costs of $200 to $240 for Two Days of Post-Surgical Pain Management
Additionally, Results of Independent Survey Show IV PCA a Burden for Postoperative Care Nurses Both Cost Analysis and Survey Findings Underscore Need for Cost-Effective, Patient and Nurse Friendly In-Hospital Pain Management Innovations REDWOOD CITY, Calif.
Toggle Summary AcelRx Pharmaceuticals Announces The Departure Of David Chung
REDWOOD CITY, Calif. , June 2, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that David Chung has
Toggle Summary AcelRx Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
REDWOOD CITY, Calif. , May 29, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will
Toggle Summary AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
REDWOOD CITY, Calif. , May 19, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Reports First Quarter 2014 Financial Results
REDWOOD CITY, Calif. , May 8, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the
Toggle Summary AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 8, 2014
REDWOOD CITY, Calif. , May 2, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first
Toggle Summary AcelRx Pharmaceuticals Announces Zalviso™ and ARX-04 Data Presentations at the American Pain Society 33rd Annual Scientific Meeting
REDWOOD CITY, Calif. , May 1, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that multiple Zalviso and
Toggle Summary AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
REDWOOD CITY, Calif. , April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
REDWOOD CITY, Calif. , March 25, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of
Toggle Summary AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference
REDWOOD CITY, Calif. , March 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
REDWOOD CITY, Calif. , March 3, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the
Toggle Summary AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014
REDWOOD CITY, Calif. , Feb. 24, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth
Toggle Summary AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
REDWOOD CITY, Calif. , Feb. 5, 2014 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
REDWOOD CITY, Calif., Dec. 19, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has entered
Toggle Summary AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO™
- FDA establishes the PDUFA action date of July 27, 2014 for Zalviso - - Conference Call Scheduled Monday, December 16th 2013 for 8:30 a.m. Eastern Time - REDWOOD CITY, Calif. and AACHEN, Germany , Dec. 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Toggle Summary AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data at Anesthesia Medical Conference
- 30 mcg sufentanil NanoTab treatment group experienced rapid onset of action with statistically significant pain relief and reduced pain intensity at 30 minutes - REDWOOD CITY, Calif. , Dec. 13, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company
Toggle Summary AcelRx Pharmaceuticals Adds New Board Member
REDWOOD CITY, Calif. , Dec. 11, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard F.
Toggle Summary Zalviso™ New Drug Application Accepted for Filing by FDA
REDWOOD CITY, Calif. , Dec. 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the Zalviso ™ New Drug
Toggle Summary AcelRx Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
REDWOOD CITY, Calif. , Nov. 26, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
REDWOOD CITY, Calif. , Nov. 5, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX),  a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the
Toggle Summary AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013
REDWOOD CITY, Calif. , Oct. 22, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third
Toggle Summary AcelRx Pharmaceuticals Announces Data Presentations for Zalviso™ at US and International Medical Meetings
First medical meeting data presentations from Phase 3 clinical trial conducted in orthopedic surgery patients REDWOOD CITY, Calif. , Oct. 15, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of
Toggle Summary AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso™ and its Proprietary Platform Technologies
Patent estate includes nine issued U.S. patents, nineteen patents worldwide REDWOOD CITY, Calif. , Oct. 8, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment
Toggle Summary AcelRx Pharmaceuticals Submits New Drug Application to the FDA for Zalviso™
Zalviso NDA submitted for the management of moderate-to-severe acute pain in adult patients in the hospital setting REDWOOD CITY, Calif. , Sept. 30, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization
Toggle Summary David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer
REDWOOD CITY, Calif. , Sept. 4, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that David H.
Toggle Summary AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
REDWOOD CITY, Calif. , Aug. 30, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
REDWOOD CITY, Calif. , Aug. 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial
Toggle Summary AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
REDWOOD CITY, Calif. , Aug. 5, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013
REDWOOD CITY, Calif. , Aug. 2, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release second
Toggle Summary AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares
REDWOOD CITY, Calif. , July 23, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), today announced the closing of the public offering of 4,370,000 shares of common stock, including 570,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option
Toggle Summary AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif. , July 18, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 3.8 million shares of its common stock, offered at a price of $11.65 per share to the public.
Toggle Summary AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
REDWOOD CITY, Calif. , July 17, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an
Toggle Summary AcelRx Pharmaceuticals Joins Russell Global and Russell 3000 Indexes
REDWOOD CITY, Calif. , July 2, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, has joined the broad-market Russell 3000 ®
Toggle Summary AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
REDWOOD CITY, Calif. , July 1, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that on July 9, 2013 the
Toggle Summary AcelRx Pharmaceuticals to Host Investor Day on June 27, 2013
REDWOOD CITY, Calif. , June 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, will host an Investor Day on Thursday, June
Toggle Summary AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare
REDWOOD CITY, Calif. , May 29, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
- Following major orthopedic surgery, Sufentanil NanoTab-treated patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p<0.001) - - Results confirm all previously reported Phase 3 trial outcomes, supporting submission of an NDA anticipated for third
Toggle Summary AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
REDWOOD CITY, Calif. , May 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
REDWOOD CITY, Calif. , May 8, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results
Toggle Summary AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
REDWOOD CITY, Calif. , May 3, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first
Toggle Summary AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
- Additional Phase 3 analysis show significantly faster reduction in pain and fewer patients with oxygen desaturation events for Sufentanil NanoTab PCA System than IV PCA with morphine - - Sufentanil NanoTab PCA System remains on track for a Q3 2013 NDA submission - REDWOOD CITY, Calif.
Toggle Summary Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
- Patients in the 30 mcg sufentanil NanoTab treatment group experienced significantly greater reduction in pain as measured by SPID-12 vs. placebo - - ARX-04 is a rapid-onset, non-invasive investigational pain medication being evaluated for the short-term treatment of acute moderate-to-severe pain
Toggle Summary AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
REDWOOD CITY, Calif. , March 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial
Toggle Summary AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
REDWOOD CITY, Calif. , March 7, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release
Toggle Summary AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
- Patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p=0.001) - - Adverse events in sufentanil-treated patients similar to placebo - - AcelRx to conduct conference call and webcast tomorrow, March 5, at 8:30 a.m. EST (5:30 a.m.
Toggle Summary AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
REDWOOD CITY, Calif. , Feb. 27, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that AcelRx will present a
Toggle Summary AcelRx Pharmaceuticals Provides Clinical Trial Updates
Continued progress towards NDA submission for Sufentanil NanoTab PCA System in Q3 2013 REDWOOD CITY, Calif. , Feb. 19, 2013 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for
Toggle Summary AcelRx Appoints Adrian Adams to Board of Directors as Chairman
REDWOOD CITY, Calif., Feb. 12, 2013 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of
Toggle Summary AcelRx Pharmaceuticals Announces Exercise of Option to Purchase Additional Shares
REDWOOD CITY, Calif. , Dec. 14, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), announced today that the underwriters of its public offering have exercised, in full, their option to purchase an additional 1,875,000 shares of common stock at a public offering price of $3.31 per
Toggle Summary AcelRx to Present Top-Line Data from Phase 3 Study of Sufentanil NanoTab® PCA System vs. IV PCA Morphine at the 66th Annual PostGraduate Assembly in Anesthesiology held in New York City
- First medical meeting presentation of top-line Phase 3 data demonstrating NanoTab System met both non-inferiority and superiority comparisons to IV PCA with morphine in open-label study - REDWOOD CITY, Calif. , Dec. 14, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.
Toggle Summary AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif. , Dec. 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), today announced the pricing of its previously announced underwritten public offering of 12,500,000 shares of its common stock, offered at a price of $3.31 per share to the public.  The gross proceeds to
Toggle Summary AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
REDWOOD CITY, Calif. , Dec. 5, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), today announced a proposed underwritten public offering of 10,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission (" SEC ").  
Toggle Summary AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 20, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain
-In this open-label study, the Sufentanil NanoTab PCA System also demonstrated statistical superiority to IV PCA morphine for primary endpoint of Patient Global Assessment of method of pain control - Nurses and patients rated Sufentanil NanoTab PCA System higher for Overall Satisfaction and Ease of
Toggle Summary AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
REDWOOD CITY, Calif. , Nov. 14, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today it had met the primary
Toggle Summary AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
REDWOOD CITY, Calif. , Nov. 6, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the
Toggle Summary AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
- Phase 2 placebo-controlled, dose-finding study funded by a grant from the Department of Defense - REDWOOD CITY, Calif. , Nov. 5, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative
Toggle Summary AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
REDWOOD CITY, Calif. , Nov. 1, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third
Toggle Summary AcelRx Receives Notice of Eligibility for Centralized Review from European Medicines Agency for the Sufentanil NanoTab® PCA System
Centralized review process used for products that provide a significant therapeutic, scientific or technical innovation to patient health REDWOOD CITY, Calif. , Oct. 3, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development
Toggle Summary AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
REDWOOD CITY, Calif. , Sept. 18, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Mike A.
Toggle Summary AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
REDWOOD CITY, Calif. , Sept. 10, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
Two more U.S. patents expand intellectual property protection for AcelRx's pipeline of sufentanil NanoTab® pain products REDWOOD CITY, Calif. , Aug. 29, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Initiates Third Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab® PCA System, for the Treatment of Post-Operative Pain
First orthopedic surgery patient dosed in randomized, double-blind, placebo-controlled trial REDWOOD CITY, Calif. , Aug. 23, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies
Toggle Summary AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
REDWOOD CITY, Calif. , Aug. 23, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
REDWOOD CITY, Calif. , Aug. 9, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial
Toggle Summary AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
REDWOOD CITY, Calif. , Aug. 8, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. ("AcelRx") (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that Richard
Toggle Summary AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
REDWOOD CITY, Calif. , Aug. 7, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release second
Toggle Summary AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
Two new U.S. patents expand intellectual property protection for AcelRx pipeline of sufentanil NanoTab® pain products REDWOOD CITY, Calif. , Aug. 1, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization
Toggle Summary AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Company invites individual and institutional investors to log-on to view July 12th presentation NEW YORK , July 20, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the
Toggle Summary AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK , July 10, 2012  /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies
Toggle Summary AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2012
REDWOOD CITY, Calif. , June 28, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
- First U.S. patent provides intellectual property protection for AcelRx pipeline of NanoTab® pain products through 2030- REDWOOD CITY, Calif. , June 20, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
REDWOOD CITY, Calif. , June 4, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. ("AcelRx") (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that Richard King
Toggle Summary AcelRx Pharmaceuticals Completes Private Placement of $10.0 Million
REDWOOD CITY, Calif. , June 4, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that it completed its
Toggle Summary AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
REDWOOD CITY, Calif. , May 30, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that it has obtained
Toggle Summary AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
REDWOOD CITY, Calif. , May 8, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results
Toggle Summary AcelRx Pharmaceuticals Announces Hiring of Kim Gaumer as Vice President, Regulatory Affairs and Quality Assurance
REDWOOD CITY, Calif., April 17, 2012 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of
Toggle Summary AcelRx Announces Initiation of Second Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab® PCA System, for the Treatment of Acute Post-Operative Pain
First Subject Dosed in Open-Label, Active-Comparator Trial REDWOOD CITY, Calif., April 12, 2012 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the
Toggle Summary AcelRx Pharmaceuticals Receives Two Notices of Allowance for Small-Volume Oral Transmucosal Dosage Forms
First US allowances could provide for intellectual property protection for AcelRx pipeline of NanoTab® pain products until at least 2029. REDWOOD CITY, Calif. , April 11, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
REDWOOD CITY, Calif. , March 20, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial
Toggle Summary AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain
First Subject Dosed in Abdominal Surgery Trial with Top-Line Data Expected in H2 2012 REDWOOD CITY, Calif. , March 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative
Toggle Summary AcelRx Pharmaceuticals to Present at Two Near-Term Health Care Conferences
REDWOOD CITY, Calif. , Feb. 21, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012
   REDWOOD CITY, Calif. , Jan. 31, 2012 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported that the two
Toggle Summary AcelRx Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
REDWOOD CITY Calif. , Nov. 23, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Reports Third Quarter 2011 Financial Results
REDWOOD CITY, Calif., Nov. 8, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial
Toggle Summary AcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors
REDWOOD CITY, Calif., Sept. 28, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc., (NASDAQ: ACRX) ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced that Mark
Toggle Summary AcelRx Pharmaceuticals to Present at Two Healthcare Investor Conferences in the Second Half of September
REDWOOD CITY, Calif., Sept. 15, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard
Toggle Summary AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
REDWOOD CITY, Calif., Sept. 9, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King
Toggle Summary AcelRx Pharmaceuticals to Present at the Southern California Investor Conference
REDWOOD CITY, Calif., Aug. 25, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King
Toggle Summary AcelRx Pharmaceuticals Reports Second Quarter 2011 Financial Results
Remains On Track to Initiate First ARX-01 Phase 3 Clinical Trial Later This Year REDWOOD CITY, Calif., Aug. 11, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative
Toggle Summary AcelRx Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
REDWOOD CITY, Calif., Aug. 10, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King
Toggle Summary AcelRx Secures $20 Million Loan Financing Agreement, Expected to Extend Its Operating Cash Runway Into 2013
REDWOOD CITY, Calif., June 30, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx) today announced that it has obtained a $20 million secured loan agreement with Hercules Technology Growth Capital (Hercules). Upon the execution of this agreement with Hercules,
Toggle Summary AcelRx Announces $5.6 Million Department of Defense Grant to Develop ARX-04, a New Acute Pain Product Candidate
REDWOOD CITY, Calif., May 31, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)(AcelRx), today announced that the US Army Medical Research and Material Command (USAMRMC) has awarded AcelRx a $5.6 million grant to support the development of a new product candidate, ARX-04,
Toggle Summary ARX-01 and ARX-03 Clinical Results Presented at the 30th Annual Scientific Meeting of the American Pain Society
REDWOOD CITY, Calif., May 18, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. announced today that the results from its Phase 2 clinical studies related to two product candidates, ARX-01 Sufentanil NanoTab(R) PCA System, which is designed to solve the problems associated with
Toggle Summary AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results
Initiation of Phase 3 Trial for Lead Product Candidate ARX-01 On Track for Second Half of 2011 REDWOOD CITY, Calif., May 12, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization
Toggle Summary AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
REDWOOD CITY, Calif., May 10, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc., (NASDAQ: ACRX) ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced that the
Toggle Summary AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
REDWOOD CITY, Calif., May 6, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King ,
Toggle Summary AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
Plans to Initiate the Phase 3 Program for Lead Product Candidate ARX-01 in Second Half of 2011; IPO Completed REDWOOD CITY, Calif., March 24, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
REDWOOD CITY, Calif., March 7, 2011 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King
Toggle Summary AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
REDWOOD CITY, Calif. , Feb. 11, 2011 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the pricing of its initial public
Toggle Summary AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
REDWOOD CITY, Calif., Nov. 12, 2010 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.
Toggle Summary AcelRx Pharmaceuticals Hires James Welch as Chief Financial Officer
REDWOOD CITY, Calif., October 4, 2010 – AcelRx Pharmaceuticals, Inc. announced today that James H. Welch has joined the company as Chief Financial Officer. “We are very fortunate to continue to attract seasoned leaders in the pharmaceutical industry” stated Richard King, AcelRx President and CEO.
Toggle Summary AcelRx Announces Completion of an End of Phase 2 Meeting with FDA for ARX-02, Sufentanil NanoTab™ Breakthrough Pain Management System
REDWOOD CITY, Calif., October 1, 2010 -- AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTabTM Breakthrough Pain Management System for the treatment of cancer
Toggle Summary AcelRx Announces Positive Phase 2 Results from a Study of ARX-02 Sufentanil NanoTab™ Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
Study achieved primary and secondary endpoints and showed rapid onset of pain relief in cancer patients experiencing breakthrough pain REDWOOD CITY, Calif., May 25, 2010 – AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy
Toggle Summary AcelRx Sufentanil NanoTab PCA System (ARX-01) Phase 2 Results Featured in Poster Presentations at the 35th Annual Meeting of the American Society of Regional Anesthesia and Pain to be held in Toronto on April 22-25th
REDWOOD CITY, Calif., April 20, 2010 -- AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 2 studies evaluating the safety and efficacy of the ARX-01 sublingual Sufentanil NanoTabTM PCA System will be featured in three poster presentations at the upcoming 35th Annual Regional
Toggle Summary AcelRx Pharmaceuticals Names Richard King Chief Executive Officer
REDWOOD CITY, Calif., April 6, 2010 -- AcelRx Pharmaceuticals, Inc. today announced the appointment of Richard King as president and chief executive officer. Mr. King will lead AcelRx’s efforts to advance the Company’s portfolio of products using its novel NanoTab™ platform technology.
Toggle Summary AcelRx to Present at the Lazard 6th Annual Healthcare Conference
REDWOOD CITY, Calif., November 13, 2009 -- AcelRx Pharmaceuticals, Inc. today announced that Thomas Schreck, President & Chief Executive Officer, and Pamela Palmer, MD, PhD, Chief Medical Officer, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference to be held November
Toggle Summary AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management (PDF)
Toggle Summary AcelRx Announces Positive Results from a Phase 2 Study of ARX-03, a Sufentanil/Triazolam NanoTab for Procedural Sedation, Anxiolysis & Analgesia
REDWOOD CITY, Calif., October 22, 2009 -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam. ARX-03 is designed to address the current unmet
Toggle Summary AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
Two abstracts selected for oral presentations Tuesday, October 20 in New Orleans REDWOOD CITY, Calif., October 15, 2009 -- AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 1 studies evaluating the pharmacokinetics of its oral transmucosal NanoTab™ formulation of sufentanil
Toggle Summary AcelRx Pharmaceuticals Hires Nigel Ray as Vice President of Business Development
REDWOOD CITY, Calif., October 14, 2009 -- AcelRx Pharmaceuticals, Inc. announced today that Nigel Ray has joined the company as Vice President of Business Development. In this new position, Mr. Ray will lead AcelRx’s partnering efforts for its mid- and late-stage clinical products including the
Toggle Summary AcelRx Announces Perfect Performance of Handheld Component of ARX-01 Sufentanil NanoTab PCA System in a Phase 2 Study
Efficacy consistent with positive results from earlier placebo-controlled studies REDWOOD CITY, Calif., July 22, 2009 -- AcelRx Pharmaceuticals, Inc. today announced positive results from its first Phase 2 clinical study evaluating the functionality of the handheld device component of its ARX-01
Toggle Summary AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
Study in major abdominal surgery patients achieved primary and secondary endpoints REDWOOD CITY, Calif., June 29, 2009 -- AcelRx Pharmaceuticals, Inc. today announced positive results from the second Phase 2 clinical study evaluating the safety and efficacy of its ARX-01 Sufentanil NanoTabs™ for
Toggle Summary AcelRx Initiates a Phase 2 Study to Evaluate Functionality of its ARX-01 Sufentanil NanoTab PCA System
REDWOOD CITY, Calif., May 5, 2009 -- AcelRx Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical trial of its ARX-01 Sufentanil NanoTab™ PCA System, a proprietary drug/device combination product candidate being developed for management of acute post-operative pain in the
Toggle Summary AcelRx Announces Initiation of Phase 2 Cancer Breakthrough Pain Program
REDWOOD CITY, Calif., April 22, 2009 -- AcelRx Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab™ product candidate for cancer breakthrough pain control. The primary objective of this multicenter, randomized,
Toggle Summary Mark Evashenk new Vice President, Clinical Operations press release
REDWOOD CITY, Calif., March 6, 2009 -- AcelRx Pharmaceuticals, Inc. announced today it has hired Mark Evashenk as Vice President, Clinical Operations. In this new position, Mr. Evashenk will assist in defining developmental strategy, guiding clinical protocol design and study conduct, and managing
Toggle Summary AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab™
REDWOOD CITY, Calif., January 12, 2009 ‐‐ AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain management, today announced positive results from a Phase 1 clinical study
Toggle Summary AcelRx Pharmaceuticals Scheduled to Present at the JP Morgan Healthcare Conference in San Francisco on January 15, 2009
REDWOOD CITY, Calif., December 23, 2008 -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute conditions, with an initial emphasis on pain management, announced that it will present at JP Morgan’s 27th Annual Healthcare
Toggle Summary AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study
REDWOOD CITY, Calif., December 9, 2008 ‐‐ AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX‐01, for the treatment of moderate‐to‐severe inpatient acute pain following knee replacement